Related Experiment Video
Updated: Aug 10, 2026
10:57
Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018
Noncoding RNA Transcripts Based Molecular Phenotyping of MASLD and MASH Patients
Frida M Delgadillo1, Karla Perez2,3, Barbara Yang1
1Department of Biological Sciences, The University of Texas at El Paso, El Paso, Texas, USA.
Liver International Communications
|August 8, 2026
Summary
This study identifies specific noncoding RNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). These findings offer potential new biomarkers for early diagnosis and novel therapeutic targets for liver disease progression.
Area of Science:
- Molecular biology
- Genomics
- Hepatology
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH), are characterized by hepatic fat accumulation.
- These conditions can progress to severe liver damage, including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
- Timely diagnosis and management are crucial, necessitating advanced molecular phenotyping.
Purpose of the Study:
- To identify differentially expressed noncoding genes in MASLD and MASH patient samples.
- To expand the options for diagnostic and therapeutic strategies for these liver conditions.
- To explore the potential of noncoding RNAs as biomarkers and therapeutic targets.
Main Methods:
- Data extraction from a transcriptomic study on MASLD and MASH patient samples.
- Focus on transcripts with limited coding potential, specifically long noncoding RNAs (lncRNAs).
- Utilized the Genomic Regions Enrichment of Annotations Tool (GREAT) for functional relevance assessment.
Main Results:
- Identified differentially expressed lncRNAs specific to MASLD and MASH.
- Discovered 49 up-regulated lncRNAs unique to MASLD (e.g., MYCNOS) and 88 unique to MASH (e.g., ELFN2-208).
- Found 93 down-regulated noncoding transcripts unique to MASLD (e.g., AADACL2-AS1) and 132 unique to MASH (e.g., SYBU-AS1).
Conclusions:
- This research highlights the significance of noncoding RNAs in MASLD and MASH.
- Identified lncRNAs can serve as potential biomarkers for early diagnosis of liver diseases.
- These findings pave the way for novel therapeutic targets to prevent advanced liver conditions like HCC.
